E. Nuermberger

Hyaluronidase impacts exposures of long-acting injectable paliperidone palmitate in rodent models

This study evaluates how hyaluronidase affects the release and pharmacokinetics of a long-acting injectable drug in mice and rats.

Contezolid can replace linezolid in a novel combination with bedaquiline and pretomanid in a murine model of tuberculosis

The paper evaluates contezolid as a potential replacement for linezolid in combination with bedaquiline and pretomanid in a murine tuberculosis model, finding comparable activity and no cross-resistance.

Using dynamic oral dosing of rifapentine and rifabutin to simulate exposure profiles of long-acting formulations in a mouse model of tuberculosis preventive therapy

Prospectively predicting BPaMZ Phase IIb outcomes using a translational preclinical mouse to human platform

This paper predicts outcomes of BPaMZ tuberculosis treatment regimens using a translational preclinical mouse to human platform, showing potential to shorten treatment duration and prevent relapse.

Translational predictions of phase 2a first-in patient efficacy studies for antituberculosis drugs

The paper predicts clinical efficacy of antituberculosis drugs using preclinical PKPD data and translational pharmacology models to reduce phase 2a trial costs and failures.

Next-generation diarylquinolines improve sterilizing activity of regimens with pretomanid and the novel oxazolidinone TBI-223 in a mouse tuberculosis model

This study evaluates new tuberculosis treatments in mice, finding that replacing bedaquiline with TBAJ-587 reduces relapse, while replacing linezolid with TBI-223 has no significant effect.

GSK2556286 is a novel antitubercular drug candidate effective in vivo with the potential to shorten tuberculosis treatment

Novel regimens of bedaquiline-pyrazinamide combined with moxifloxacin, rifabutin, delamanid and/or OPC-167832 in murine tuberculosis models

This paper tests novel tuberculosis treatment regimens in mice, finding that BZM-based regimens show improved sterilizing activity compared to standard care.

Model-Based Meta-Analysis of Relapsing Mouse Model Studies from the Critical Path to Tuberculosis Drug Regimens Initiative Database

The paper performs a model-based meta-analysis of relapsing mouse model studies to compare TB drug regimen efficacy across multiple studies.

In vitro activity of bedaquiline and imipenem against actively growing, nutrient-starved, and intracellular Mycobacterium abscessus

This study evaluates the in vitro activity of bedaquiline and imipenem against M. abscessus under different growth conditions, finding varying interactions between the drugs.

Impact of dose, duration and host immune status on ultrashort telacebec treatment in a mouse model of Buruli ulcer

This study evaluates the efficacy of ultrashort telacebec treatment in mouse models of Buruli ulcer, finding that total dose is more critical than duration and that resistance can emerge in immunocompromised hosts.

Ultrashort treatment with telacebec alone and with companion drugs in immunocompetent and immunosuppressed mouse footpad models of Buruli ulcer

This study evaluates the efficacy of telacebec alone and with companion drugs in reducing treatment duration for Buruli ulcer in immunocompetent and immunosuppressed mice.

Dual mTORC1/mTORC2 inhibition as a Host-Directed Therapeutic Target in Pathologically Distinct Mouse Models of Tuberculosis

This study compares the efficacy of mTOR inhibitors in tuberculosis treatment, finding that CC214-2 reduces relapses more than rapamycin in mouse models.

Comparative efficacy of the novel diarylquinoline TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse model of tuberculosis

This study compares the efficacy of TBAJ-587 and bedaquiline against a resistant Rv0678 mutant in a mouse tuberculosis model, finding TBAJ-587 more effective and less prone to resistance.

Differential in vitro activity of individual drugs and bedaquiline-rifabutin combinations against actively multiplying and nutrient-starved Mycobacterium abscessus

The paper evaluates the in vitro activity of drugs and drug combinations against different growth states of M. abscessus, finding that bedaquiline-rifabutin combinations show potent bactericidal effects.

Mutations in fbiD(Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis

This study identifies mutations in fbiD(Rv2983) as a novel determinant of resistance to pretomanid and delamanid in Mycobacterium tuberculosis through in vitro and in vivo experiments.

Preserved efficacy and reduced toxicity with intermittent linezolid dosing in combination with bedaquiline and pretomanid in a murine TB model

Telacebec for ultra-short treatment of Buruli ulcer in a mouse model

This study evaluates Telacebec's efficacy in shortening Buruli ulcer treatment in mice, showing it can cure infections in as little as 1 week with no relapse.

New β-Lactamase Inhibitors Nacubactam and Zidebactam Improve the In Vitro Activity of β-Lactam Antibiotics Against Mycobacterium abscessus Complex Clinical Isolates

Activity of a long-acting injectable bedaquiline formulation in a paucibacillary mouse model of latent tuberculosis infection

This study evaluates a long-acting injectable bedaquiline formulation in a mouse model of latent tuberculosis, showing its efficacy with fewer doses compared to daily oral regimens.

Contribution of pretomanid to novel regimens containing bedaquiline with either linezolid or moxifloxacin and pyrazinamide in murine models of tuberculosis

This study shows pretomanid improves the efficacy of TB treatment regimens in mice by reducing relapse and bedaquiline resistance.

In vitro activity of the new β-lactamase inhibitors relebactam and vaborbactam in combination with β-lactams against Mycobacterium abscessus complex clinical isolates

This study evaluates the in vitro activity of β-lactamase inhibitors relebactam and vaborbactam with β-lactams against MABC clinical isolates, showing improved anti-MABC activity.

Mutations in Rv2983 as a novel determinant of resistance to nitroimidazole drugs in Mycobacterium tuberculosis

This paper identifies Rv2983 as a novel gene conferring resistance to nitroimidazole drugs in Mycobacterium tuberculosis and highlights the challenges in detecting such resistance.

High-dose rifamycins enable shorter oral treatment in a murine model of Mycobacterium ulcerans disease

This study evaluates higher doses of rifamycins in a mouse model of Buruli ulcer, finding dose-dependent efficacy and potential for shorter treatment regimens.